

Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)

Review Questions

NICE guideline NG101

Review Questions

January 2025

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2025. All rights reserved. Subject to [Notice of rights](#).

Contents

1	Review Questions.....	5
---	-----------------------	---

1 Review Questions

Review Question 1.1: What is the clinical and cost effectiveness of adding a platinum to a taxane based neoadjuvant chemotherapy regimen with or without an anthracycline in people with invasive breast cancer that is either:

- triple negative, or
- of any receptor subtype with a BRCA germline mutation?

Review Question 1.2: What is the clinical and cost effectiveness of a neoadjuvant chemotherapy regimen containing a platinum and a taxane compared to a regimen containing an anthracycline and a taxane in people with HER2 positive invasive breast cancer?

Review Question 2.1: What is the clinical and cost-effectiveness of ovarian function suppression combined with endocrine therapy using tamoxifen or aromatase inhibitors in people with oestrogen receptor positive invasive breast cancer that is local or locally advanced who have female reproductive organs and are premenopausal or perimenopausal?

Review Question 2.2: What is the clinical and cost effectiveness of testicular function suppression combined with aromatase inhibitors compared to tamoxifen or aromatase inhibitors alone in people with ER positive invasive breast cancer who have male reproductive organs?